Amoy Diagnostics Bilan de santé

Santé financière contrôle des critères 5/6

Amoy Diagnostics possède un total de capitaux propres de CN¥1.8B et une dette totale de CN¥52.9M, ce qui porte son ratio d'endettement à 2.9%. Son actif total et son passif total sont CN¥2.0B et de CN¥227.1M. L'EBIT de Amoy Diagnostics est CN¥326.0M ce qui fait que son ratio de couverture des intérêts -13.4. Elle dispose de liquidités et de placements à court terme de CN¥1.1B.

Informations clés

2.9%

Ratio d'endettement

CN¥52.95m

Dette

Ratio de couverture des intérêts	-13.4x
Argent liquide	CN¥1.09b
Fonds propres	CN¥1.81b
Total du passif	CN¥227.13m
Total des actifs	CN¥2.04b

Mises à jour récentes de la santé financière

Amoy Diagnostics (SZSE:300685) Could Easily Take On More Debt

Apr 18

Recent updates

Amoy Diagnostics Co., Ltd.'s (SZSE:300685) Earnings Haven't Escaped The Attention Of Investors

Sep 18

Are Investors Undervaluing Amoy Diagnostics Co., Ltd. (SZSE:300685) By 23%?

Aug 23

Amoy Diagnostics' (SZSE:300685) Upcoming Dividend Will Be Larger Than Last Year's

May 27

Earnings Report: Amoy Diagnostics Co., Ltd. Missed Revenue Estimates By 6.1%

Apr 24

Amoy Diagnostics (SZSE:300685) Could Easily Take On More Debt

Apr 18

What Amoy Diagnostics Co., Ltd.'s (SZSE:300685) 33% Share Price Gain Is Not Telling You

Mar 02

Is Amoy Diagnostics Co., Ltd. (SZSE:300685) Worth CN¥22.0 Based On Its Intrinsic Value?

Mar 01

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de 300685 ( CN¥1.7B ) dépassent ses passifs à court terme ( CN¥216.3M ).

Passif à long terme: Les actifs à court terme de 300685 ( CN¥1.7B ) dépassent ses passifs à long terme ( CN¥10.8M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: 300685 dispose de plus de liquidités que de sa dette totale.

Réduire la dette: Le ratio d'endettement de 300685 est passé de 0% à 2.9% au cours des 5 dernières années.

Couverture de la dette: La dette de 300685 est bien couverte par le flux de trésorerie opérationnel ( 611.4% ).

Couverture des intérêts: 300685 gagne plus d'intérêts qu'il n'en paie, donc la couverture des paiements d'intérêts n'est pas un problème.

Amoy Diagnostics Bilan de santé

Santé financière contrôle des critères 5/6

Informations clés

Mises à jour récentes de la santé financière

Amoy Diagnostics (SZSE:300685) Could Easily Take On More Debt

Recent updates

Price target increased by 7.0% to CN¥28.92

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

New minor risk - Share price stability

Amoy Diagnostics Co., Ltd. to Report Q3, 2024 Results on Oct 22, 2024

Investor sentiment improves as stock rises 35%

Amoy Diagnostics Co., Ltd.'s (SZSE:300685) Earnings Haven't Escaped The Attention Of Investors

Now 20% undervalued

Are Investors Undervaluing Amoy Diagnostics Co., Ltd. (SZSE:300685) By 23%?

Amoy Diagnostics Co., Ltd. Elects Shen Zhe and Wu Qiao as Independent Director

Now 20% undervalued after recent price drop

Second quarter 2024 earnings: Revenues and EPS in line with analyst expectations

Now 20% undervalued after recent price drop

Amoy Diagnostics Co., Ltd. to Report First Half, 2024 Results on Jul 30, 2024

Amoy Diagnostics' (SZSE:300685) Upcoming Dividend Will Be Larger Than Last Year's

Dividend increased to CN¥0.15

Amoy Diagnostics Co., Ltd. Announces Cash Dividend on A Shares for the Year 2023, Payable on 30 May 2024

Earnings Report: Amoy Diagnostics Co., Ltd. Missed Revenue Estimates By 6.1%

Amoy Diagnostics (SZSE:300685) Could Easily Take On More Debt

Full year 2023 earnings: EPS exceeds analyst expectations

Amoy Diagnostics Co., Ltd., Annual General Meeting, May 13, 2024

Amoy Diagnostics Co., Ltd. (SZSE:300685) commences an Equity Buyback Plan for CNY 200 million worth of its shares, under the authorization approved on February 26, 2024.

Amoy Diagnostics Co., Ltd. to Report Q1, 2024 Results on Apr 23, 2024

Price target decreased by 7.6% to CN¥29.52

What Amoy Diagnostics Co., Ltd.'s (SZSE:300685) 33% Share Price Gain Is Not Telling You

Is Amoy Diagnostics Co., Ltd. (SZSE:300685) Worth CN¥22.0 Based On Its Intrinsic Value?

Now 24% overvalued

Investor sentiment improves as stock rises 20%

New minor risk - Share price stability

Amoy Diagnostics Co., Ltd. to Report Fiscal Year 2023 Results on Apr 16, 2024

Amoy Diagnostics Co., Ltd.(SZSE:300685) dropped from Shenzhen Stock Exchange Component Index

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Amoy Diagnostics Co., Ltd. to Report Q3, 2023 Results on Oct 24, 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Amoy Diagnostics Co., Ltd. to Report First Half, 2023 Results on Aug 01, 2023

Amoy Diagnostics Co., Ltd. Announces 2022 Final Profit Distribution Plan to Be Implemented (A Shares), Payment Date of 23 May 2023

Full year 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to CN¥35.47

Less than half of directors are independent

Consensus revenue estimates fall by 18%

Price target decreased to CN¥41.29

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment improved over the past week

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Amoy Diagnostics Co., Ltd., Annual General Meeting, Jun 20, 2022

Amoy Diagnostics Co., Ltd. Announces Dividend, Payable on May 31, 2022

Amoy Diagnostics Co., Ltd. Approves Dividend for 2021

Price target decreased to CN¥82.96

High number of new directors

Amoy Diagnostics Co., Ltd. Announces the Profit Distribution Proposal for 2021

Price target decreased to CN¥93.33

Full year 2021 earnings: EPS and revenues miss analyst expectations

Now 22% undervalued after recent price drop

Consensus EPS estimates fall by 15%

Full year 2021 earnings: EPS and revenues miss analyst expectations

Amoy Diagnostics Co., Ltd. (SZSE:300685) announces an Equity Buyback for CNY 200 million worth of its shares.

Amoy Diagnostics Co., Ltd. and PREMIA Holdings (HK) Limited Announces the Commercial Launch of the AmoyDx® Pan Lung Cancer PCR Panel in Japan

Third quarter 2021 earnings released: EPS CN¥0.29 (vs CN¥0.21 in 3Q 2020)

Price target increased to CN¥105

Second quarter 2021 earnings released: EPS CN¥0.30 (vs CN¥0.24 in 2Q 2020)

Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd., and Precision Medicine Asia Co., Ltd. Announce the Approval of AmoyDx Pan Lung Cancer PCR Panel

Full year 2020 earnings released: EPS CN¥0.82 (vs CN¥0.63 in FY 2019)

New 90-day low: CN¥67.96

Amoy Diagnostics Co., Ltd. to Report Fiscal Year 2020 Results on Apr 13, 2021

New 90-day high: CN¥92.11

New 90-day high: CN¥87.26

New 90-day low: CN¥71.91

New 90-day low: CN¥72.29

Third quarter earnings released

New 90-day high - CN¥88.26

New 90-day high - CN¥79.53

Amoy Diagnostics Co., Ltd. to Report First Half, 2020 Results on Jul 28, 2020

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan